of high quality IVD reagents at the Trivitron Medical Technology Park will enhance access to cost effective diagnosis, said GSK Velu, founder and managing director, Trivitron Healthcare. Trivitron Medical Technology Park is South Asia’s first of its kind manufacturing facility situated at Irungattukottai near Chennai.
Helios & Matheson bags contract from US auto co
IT company Helios and Matheson Information, through its subsidiary Matheson Information Technology, has bagged a three-year contract for providing managed services to a Fortune 500 major US automotive giant. Declining to divulge the identity of the company and size of the deal, Helios and Matheson CEO and MD GK Muralikrishna said, “It is a multi-million contract and and will be adding to our revenues substantially.” He said that though the client has been associated with the company for over 13 years, the order is new.
Lamborghini global sales jump 30% in 2012
Italian luxury car-maker Lamborghini on Monday said its global sales increased by over 30% to 2,083 units in 2012 driven by robust performance in many markets, including India. “Automobili Lamborghini SpA increased worldwide deliveries to customers in 2012 from 1,602 to 2,083 units... strong demand continues for award-winning Aventador,” the company said in a statement. During the year, the Asia Pacific region contributed 35% of the global total sales. “India achieved sales growth of 21%,” Automobili Lamborghini said without sharing details.
Audi launches new version of R8 sportscar
German luxury carmaker, Audi, has launched the new version of its two-seater R8 sportscar in India priced at R1.34 crore for the V8 version and R1.57 crore for the V10 model. A V10 convertible variant is also available at R1.73 crore. The segment leader, R8 sees new headlights and improved acceleration on all models. The R8 V8 puts out 430 HP, while the V10 variant puts out 525 hp of power, propelling the car from 0 to 100 kmph in 3.6 seconds up to a top speed of 314 kmph.
Aurobindo gets FDA nod for anti-bacterial injections
Aurobindo Pharma on Monday said it has received final approvals from the US health regulator to manufacture and market Oxacillin for Injection used for treating bacterial